In cervical cancer, PD-1/CTLA-4 BSABs may confer a longer survival period than PD-L1/TGF-β BSABs (mOS, 17.5 vs. 13.4 months; Fig. 5c, e and Supplementary Table S7). This evidence concerns the gene TGFB1 and cervical cancer.